# Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT01515137** · PHASE1 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 47 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Erlotinib plus sulindac
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01515137
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515137, "Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01515137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*